Production (Stage)
Aspire Biopharma Holdings, Inc.
ASBP
$0.225
$0.0010.45%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 381.72% | 279.07% | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 419.37% | 255.65% | -- | -- | -- |
| Operating Income | -419.37% | -255.65% | -- | -- | -- |
| Income Before Tax | -3,575.08% | -284.43% | -- | -- | -- |
| Income Tax Expenses | 100.00% | 100.00% | -- | -- | -- |
| Earnings from Continuing Operations | -3,571.33% | -284.16% | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3,571.33% | -284.16% | -- | -- | -- |
| EBIT | -419.37% | -255.65% | -- | -- | -- |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -4,819.77% | -5,300.00% | -- | -- | -- |
| Normalized Basic EPS | -490.57% | -6,500.00% | -- | -- | -- |
| EPS Diluted | -4,819.77% | -5,300.00% | -- | -- | -- |
| Normalized Diluted EPS | -490.57% | -6,500.00% | -- | -- | -- |
| Average Basic Shares Outstanding | 189.96% | 205.70% | -- | -- | -- |
| Average Diluted Shares Outstanding | 189.96% | 205.70% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |